Analyst Research Report Snapshot

Title:

ACTIVE BIOTECH - LACKING A 2012 FILING

Price:

$10.00

Provider:

Edison Investment Research

Date:

03 Nov 2011

Pages:

2

Type:

AcrobatPDF

Companies referenced:

ACTI.ST

Available for Immediate Download
Summary:

The confirmation that a third Phase III study will be required to seek approval for laquinimod in the US comes as little surprise given the primary endpoint miss in the BRAVO trial in August. However, the harsh share price reaction on Active Biotech is more perplexing. The setback may provide an opportunity for partner Teva to shift the development strategy from mono- to combination therapy, a move that would have both scientific and commercial rationale. Active Biotech’s valuation is attractive based on its other Phase III programmes and ignoring laquinimod altogether.

Why buy analyst research?

  • Institutional quality research
  • Available for Immediate Download
  • Detailed company or industry insight
  • Print or save
  • 24 hour customer support
Return to previous page without adding this item to your cart.
Email Customer Support.

About Analyst Research

Analyst research reports are available for immediate download after purchase. You will have unlimited access to the report for 24 hours after purchase, to download, print or save it as many times as you wish. Analyst Research provided by Reuters does not constitute investment advice, and is not endorsed by Reuters Research. This information is protected by copyright and intellectual property laws. More information on Analyst Research.